Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03541603 · ClinicalTrials.gov registry record · Phase 2

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

A Phase 2 study, sponsored by Tenax Therapeutics.

Completed
Registry status
Phase 2
Development phase
44
Enrollment target

NCT03541603: Completed Phase 2 study, sponsored by Tenax Therapeutics.

NCT03541603 is a Phase 2 study that has completed, run by Tenax Therapeutics. The registered enrollment target is 44 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03541603, a Phase 2 study, has completed, sponsored by Tenax Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
44 participants
Enrollment target

Study Summary

Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects

Primary Outcome

Change from baseline Pulmonary Capillary Wedge Pressure (PCWP) with bicycle exercise at Week 6

Interventions

  • DRUG Matching Placebo
  • DRUG Levosimendan

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2018-11-14
Est. Completion 2020-04-07
Phase Phase 2
Tenax Therapeutics

6 total trials

What the finished NCT03541603 record still lists

NCT03541603 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.

NCT03541603 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03541603 about?

NCT03541603 is a clinical study titled "Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF". Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects

What is the current status of trial NCT03541603?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2018-11-14. Estimated completion is 2020-04-07.

What interventions are being tested in trial NCT03541603?

The interventions under investigation include: Matching Placebo (DRUG), Levosimendan (DRUG).

Who is sponsoring clinical trial NCT03541603?

This trial is sponsored by Tenax Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03541603's enrollment target sits among peer trials

44 1322nd of 2000 higher than 669 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03541603, the US trial registry maintained by the National Library of Medicine. NCT03541603 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.